Cargando…
Short duration, high dose, alternating chemotherapy in metastatic neuroblastoma. (ENSG 3C induction regimen). The European Neuroblastoma Study Group.
Fifty-one children, aged from 15 months to 13 years 5 months with metastatic neuroblastoma presenting sequentially at the participating institutions received four 3 to 4 weekly courses of high dose multiagent chemotherapy. High dose cisplatin (200 mg m-2) combined with etoposide (500 mg m-2), HIPE,...
Autores principales: | Pinkerton, C. R., Zucker, J. M., Hartmann, O., Pritchard, J., Broadbent, V., Morris-Jones, P., Breatnach, F., Craft, A. E., Pearson, A. D., Wallendszus, K. R. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1990
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971805/ https://www.ncbi.nlm.nih.gov/pubmed/2386751 |
Ejemplares similares
-
Where next with therapy in advanced neuroblastoma?
por: Pinkerton, C. R.
Publicado: (1990) -
BIRICODAR (VX-710; Incel™): an effective chemosensitizer in neuroblastoma
por: Yanagisawa, T, et al.
Publicado: (1999) -
Neuroblastoma
por: Pearson, D.
Publicado: (1977) -
Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study.
por: Philip, T., et al.
Publicado: (1993) -
Pharmacological targets for the induction of ferroptosis: Focus on Neuroblastoma and Glioblastoma
por: Ferrada, Luciano, et al.
Publicado: (2022)